FDA Urges Restrictions, Education on Illegal 7-OH Opioid Products
By Stephanie Brown HealthDay Reporter
Medically reviewed by Drugs.com
TUESDAY, July 29, 2025 -- The U.S. Food and Drug Administration is recommending that certain products containing 7-hydroxymitragynine (7-OH) -- an illegal opioid easily accessible in high-concentration versions online and at gas stations, corner stores, and vape shops -- be controlled under the Controlled Substances Act.
A concentrated compound derived from the kratom plant, 7-OH has a great potential for abuse. The agency is not focusing on natural kratom leaf products. A new report issued by the FDA aims to inform the public about the health risks of 7-OH and to clarify how it differs from the kratom leaf.
The FDA recommendation follows a detailed scientific review and is part of broader efforts to address concerns about the rise of 7-OH opioid products. Currently, 7-OH has no FDA-approved drug uses and is not legally permitted in dietary supplements or conventional foods.
The FDA has issued educational materials to inform consumers about the dangers of 7-OH products, as well as warning letters to seven companies for illegally selling 7-OH in forms like tablets, gummies, drink mixes, and shots. The FDA is also alerting health care professionals about the risks of these products.
"Vape stores are popping up in every neighborhood in America, and many are selling addictive products like concentrated 7-OH. After the last wave of the opioid epidemic, we cannot get caught flat-footed again," FDA Commissioner Marty Makary, M.D., M.P.H., said in a statement. "7-OH is an opioid that can be more potent than morphine. We need regulation and public education to prevent another wave of the opioid epidemic."
The Drug Enforcement Agency is reviewing the FDA recommendation on 7-OH and holds final authority on drug classification, which involves public input before any decision is finalized.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.